share_log

Femasys Initiates Enrollment In Pivotal Trial Of Its Permanent Birth Control Candidate FemBloc

Benzinga ·  Aug 3, 2023 08:49

Femasys Inc. (NASDAQ:FEMY), a biomedical company focused on meeting women's unmet needs worldwide by developing a broad portfolio of innovative product candidates and products that include minimally invasive, in-office technologies for reproductive health, announced the initiation of enrollment in a prospective multi-center pivotal trial for FemBloc INtratubal Occlusion for TranscervicAL PErmanent Birth Control (the "FINALE" trial), to investigate the safety and efficacy of its investigational permanent birth control candidate, FemBloc. The robust trial is designed to address the high unmet need that exists for women seeking permanent birth control for whom elective surgery remains the only option.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment